Preparation and biological assessment of 177Lu-BPAMD as a high potential agent for bone pain palliation therapy: comparison with 177Lu-EDTMP

详细信息    查看全文

• 作者：Hassan Yousefnia ; Samaneh Zolghadri…
• 关键词：177Lu ; BPAMD ; Biodistribution ; Bone pain palliation
• 刊名：Journal of Radioanalytical and Nuclear Chemistry
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：307
• 期：2
• 页码：1243-1251
• 全文大小：1,169 KB
• 参考文献：1.Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E (2003) Holland-Frei Cancer Medicine. 6th edn. Hamilton (ON), BC Decker
  2.IAEA-TECDOC-1549 (2007) Criteria for palliation of bone metastases—clinical applications, IAEA, Austria, Vienna
  3.Lipton A (2004) Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2:205–220
  4.Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423–1436CrossRef
  5.Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F, Gordon EE (1993) 153Samarium-EDTMP biodistribution and dosimetry estimation. J Nucl Med 34:1031–1036
  6.Rajendran JG, Eary JF, Bensinger W, Durack LD, Vernon C, Fritzberg A (2002) High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med 43:1383–1390
  7.Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A (1992) 153Samarium-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 33:1451–1458
  8.Kálmán FK, Király R, Brücher E (2008) Stability constants and dissociation rates of the EDTMP complexes of samarium(III) and yttrium(III). Eur J Inorg Chem 30:4719–4727CrossRef
  9.Beyer GJ, Offord R, Künzi G, Aleksandrova Y, Ravn U, Jahn S, Barker J, Tengblad O, Lindroos M (1997) The influence of EDTMP concentration on the biodistribution of radio-lanthanides and 225Ac in tumor-bearing mice. Nucl Med Biol 24:367–372CrossRef
  10.Fellner M, Riss P, Loktionova N, Zhernosekov KP, Thews O, Geraldes CFGC, Kovacs Z, Lukeš I, Rösch F (2011) Comparison of different phosphorus-containing ligands complexing 68Ga for PET-imaging of bone metabolism. Radiochim Acta. 99:43–51CrossRef
  11.Fellnera M, Biesalski B, Bausbacher N, Kubícek V, Hermann P, Rösch F, Thews O (2012) 68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter. Nucl Med Biol 39:993–999CrossRef
  12.Fellner M, Baum RP, Kubícek V, Hermann P, Lukeš I, Prasad V, Rösch F (2010) PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human study. Eur J Nucl Med Mol Imaging 37:834CrossRef
  13.Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, Zaknun JJ (2013) Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med 38:88–92CrossRef
  14.Fellner M, Baum R, Kubicek V, Hermann P, Roesch F (2010) 177Lu-BPAMD-From bone imaging to therapy with a macrocycle-bisphosphonate ligand. J Nucl Med 51:1164
  15.Yousefnia H, Amraei N, Hosntalab M, Zolghadri S, Bahrami-samani A (2015) Preparation and biological evaluation of 166Ho-BPAMD as a potential therapeutic bone-seeking agent. J Radioanal Nucl Chem. doi:10.​1007/​s10967-014-3924-1
  16.Bahrami-Samania A, Anvari A, Jalilian AR, Shirvani-Arania S, Yousefniaa H, Aghamiri MR, Ghannadi-Maragheh M (2012) Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials. Iran J Pharm Res 11:137–144
  17.Neves M, Gano L, Pereira N, Costa MC, Costa MR, Chandia M, Rosado M, Fausto R (2002) Synthesis, characterization and biodistribution of bisphosphonates 153Sm complexes: correlation with molecular modeling interaction studies. Nucl Med Biol 29:329–338CrossRef
  18.IAEA-TECDOC-1401. (2004) Quantifying uncertainty in nuclear analytical measurements, IAEA, Austria, Vienna
  19.Meckel M. (2014) Macrocyclic bisphosphonates for PET-diagnosis and endoradiotherapy of bone metastases. http://​d-nb.​info/​1062595645/​34
  20.Deligny CL, Gelsema WJ, Tji TG, Huigen YM, Vink HA (1990) Bone seeking radiopharmaceuticals. Nucl Med Biol 17:161–791
  21.Agarwal KK, Singla S, Arora G, Bal C (2014) 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study. Eur J Nucl Med Mol Imaging 42:79–88CrossRef
  
• 作者单位：Hassan Yousefnia (1)
  Samaneh Zolghadri (1)
  Hamid Reza Sadeghi (2)
  Mojdeh Naderi (3)
  Amir Reza Jalilian (1)
  Saeed Shanehsazzadeh (1)
  
  1. Nuclear Science and Technology Research Institute (NSTRI), 14155-1339, Tehran, Iran
  2. Department of Medical Physics, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
  3. Department of Chemistry, University of Zanjan, Zanjan, Iran
  
• 刊物类别：Chemistry and Materials Science
• 刊物主题：Chemistry
  Nuclear Chemistry
  Physical Chemistry
  Nuclear Physics, Heavy Ions and Hadrons
  Diagnostic Radiology
  Inorganic Chemistry
  
• 出版者：Akad茅miai Kiad贸, co-published with Springer Science+Business Media B.V., Formerly Kluwer Academic
• ISSN：1588-2780

文摘

In this study, 177Lu-(4-{[(bis(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (177Lu-BPAMD) was successfully prepared. The quality control, partition coefficient, hydroxyapatite binding assay and stability of the complex were determined. For better comparison, biodistribution patterns of 177Lu-BPAMD and 177Lu-EDTMP complexes were compared in same animal model. 177Lu-BPAMD was prepared with high radiochemical purity (>93 %) and specific activity of 534 GBq/mmol at the optimal conditions. Comparative study between 177Lu-BPAMD and 177Lu-EDTMP indicated higher bone uptake and lesser accumulation in the other organs for 177Lu-BPAMD. 177Lu-BPAMD can be considered as a promising agent for bone pain palliation in the near future. Keywords 177Lu BPAMD Biodistribution Bone pain palliation